Why Are ChemoCentryx's Shares Trading Higher Today?

  • ChemoCentryx Inc's CCXI partner Kissei Pharmaceutical Co Ltd has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market Tavneos (avacopan).
  • Avacopan is an orally administered selective complement 5a receptor inhibitor in Japan for microscopic polyangiitis and granulomatosis with polyangiitis, forms of ANCA-associated vasculitis, or ANCA vasculitis.
  • In other countries, the PDUFA goal date for the FDA decision on the Company's amended NDA is October 7. 
  • The regulatory decision in Europe following the European Medicines Agency review is expected by the end of 2021.
  • Related Content: Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate.
  • Also Read: Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges.
  • Price Action: CCXI stock is up 6.04% at $19.29 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!